Literature DB >> 22167753

High ERp5/ADAM10 expression in lymph node microenvironment and impaired NKG2D ligands recognition in Hodgkin lymphomas.

Maria Raffaella Zocchi1, Silvia Catellani, Paolo Canevali, Sara Tavella, Anna Garuti, Barbara Villaggio, Annalisa Zunino, Marco Gobbi, Giulio Fraternali-Orcioni, Annalisa Kunkl, Jean-Louis Ravetti, Silvia Boero, Alessandra Musso, Alessandro Poggi.   

Abstract

Herein we describe that in classic Hodgkin lymphomas (cHL, n = 25) the lymph node (LN) stroma displayed in situ high levels of transcription and expression of the disulfide-isomerase ERp5 and of the disintegrin-metalloproteinase ADAM10, able to shed the ligands for NKG2D (NKG2D-L) from the cell membrane. These enzymes were detected both in LN mesenchymal stromal cells (MSCs) and in Reed-Sternberg (RS) cells; in addition, MIC-A and ULBP3 were present in culture supernatants of LN MSCs or RS cells. NKG2D-L-negative RS cells could not be killed by CD8(+)αβT or γδT cells; tumor cell killing was partially restored by treating RS cells with valproic acid, which enhanced NKG2D-L surface expression. Upon coculture with LN MSCs, CD8(+)αβT and γδT cells strongly reduced their cytolytic activity against NKG2D-L(+) targets; this seems to be the result of TGF-β, present at the tumor site, produced in vitro by LN MSCs and able to down-regulate the expression of NKG2D on T lymphocytes. In addition, CD8(+)αβT and γδT cells from the lymph nodes of cHL patients, cocultured in vitro with LN MSCs, underwent TGF-β-mediated down regulation of NKG2D. Thus, in cHL the tumor microenvironment is prone to inhibit the development of an efficient antitumor response.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22167753     DOI: 10.1182/blood-2011-07-370841

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  38 in total

Review 1.  Microenvironment abnormalities and lymphomagenesis: Immunological aspects.

Authors:  Joseph G Taylor; John G Gribben
Journal:  Semin Cancer Biol       Date:  2015-07-29       Impact factor: 15.707

2.  Panobinostat enhances NK cell cytotoxicity in soft tissue sarcoma.

Authors:  Xiuxia Lu; Mengmeng Liu; Jing Yang; Yi Que; Xing Zhang
Journal:  Clin Exp Immunol       Date:  2022-08-19       Impact factor: 5.732

Review 3.  Bone marrow niches in haematological malignancies.

Authors:  Simón Méndez-Ferrer; Dominique Bonnet; David P Steensma; Robert P Hasserjian; Irene M Ghobrial; John G Gribben; Michael Andreeff; Daniela S Krause
Journal:  Nat Rev Cancer       Date:  2020-02-28       Impact factor: 60.716

4.  Aminobisphosphonates prevent the inhibitory effects exerted by lymph node stromal cells on anti-tumor Vδ 2 T lymphocytes in non-Hodgkin lymphomas.

Authors:  Alessandra Musso; Silvia Catellani; Paolo Canevali; Sara Tavella; Roberta Venè; Silvia Boero; Ivana Pierri; Marco Gobbi; Annalisa Kunkl; Jean-Louis Ravetti; Maria Raffaella Zocchi; Alessandro Poggi
Journal:  Haematologica       Date:  2013-10-25       Impact factor: 9.941

5.  Low-dose gemcitabine induces major histocompatibility complex class I-related chain A/B expression and enhances an antitumor innate immune response in pancreatic cancer.

Authors:  Tomoharu Miyashita; Kenji Miki; Takashi Kamigaki; Isamu Makino; Hisatoshi Nakagawara; Hidehiro Tajima; Hiroyuki Takamura; Hirohisa Kitagawa; Sachio Fushida; Ali K Ahmed; Mark D Duncan; John W Harmon; Tetsuo Ohta
Journal:  Clin Exp Med       Date:  2015-10-08       Impact factor: 3.984

6.  Design, Synthesis, and Biological Evaluation of Novel Allosteric Protein Disulfide Isomerase Inhibitors.

Authors:  Suhui Yang; Andrea Shergalis; Dan Lu; Anahita Kyani; Ziwei Liu; Mats Ljungman; Nouri Neamati
Journal:  J Med Chem       Date:  2019-04-02       Impact factor: 7.446

7.  Mesenchymal stromal cells as regulators of anti-tumour immune response.

Authors:  Alessandro Poggi; M R Zocchi
Journal:  Indian J Med Res       Date:  2015-02       Impact factor: 2.375

8.  The engagement of CTLA-4 on primary melanoma cell lines induces antibody-dependent cellular cytotoxicity and TNF-α production.

Authors:  Stefania Laurent; Paola Queirolo; Silvia Boero; Sandra Salvi; Patrizia Piccioli; Simona Boccardo; Simona Minghelli; Anna Morabito; Vincenzo Fontana; Gabriella Pietra; Paolo Carrega; Nicoletta Ferrari; Francesca Tosetti; Lung-Ji Chang; Maria Cristina Mingari; Guido Ferlazzo; Alessandro Poggi; Maria Pia Pistillo
Journal:  J Transl Med       Date:  2013-05-01       Impact factor: 5.531

9.  Rescue of impaired NK cell activity in hodgkin lymphoma with bispecific antibodies in vitro and in patients.

Authors:  Katrin S Reiners; Jörg Kessler; Maike Sauer; Achim Rothe; Hinrich P Hansen; Uwe Reusch; Christian Hucke; Ulrike Köhl; Horst Dürkop; Andreas Engert; Elke Pogge von Strandmann
Journal:  Mol Ther       Date:  2013-03-05       Impact factor: 11.454

10.  Analysis of in vitro ADCC and clinical response to trastuzumab: possible relevance of FcγRIIIA/FcγRIIA gene polymorphisms and HER-2 expression levels on breast cancer cell lines.

Authors:  Silvia Boero; Anna Morabito; Barbara Banelli; Barbara Cardinali; Beatrice Dozin; Gianluigi Lunardi; Patrizia Piccioli; Sonia Lastraioli; Roberta Carosio; Sandra Salvi; Alessia Levaggi; Francesca Poggio; Alessia D'Alonzo; Massimo Romani; Lucia Del Mastro; Alessandro Poggi; Maria Pia Pistillo
Journal:  J Transl Med       Date:  2015-10-08       Impact factor: 5.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.